Lead Product(s): Adalimumab
Therapeutic Area: Immunology
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Samsung Bioepis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 16, 2020
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).